Senolytics to Improve Osteoporosis therapy: A randomised controlled clinical trial The SENIOR Trial

Recruitment & Eligibility

Status: ot Recruiting

Sex: All

Target Recruitment: 120

Inclusion Criteria

Men and women (menopause > 5 years and FSH and LH in the postmenopausal range) aged 60-90 years with a T-score < -1 at the total hip/femoral neck, or lumbar spine (increased risk for developing osteoporosis T-score -1to -2.5, or osteoporosis T-score <-2.5)., Ability to provide informed consent

Exclusion Criteria

DXA of hip or spine not possible e.g., due to a prosthesis, Subjects taking medications that are sensitive to substrates or substrates with a narrow therapeutic range for CYP3A4, CYP2C8, CYP2C9, or CYP2D6 or strong inhibitors or inducers of CYP3A4 (e.g., cyclosporine, tacrolimus or sirolimus). If antifungals are necessary from an infectious disease perspective, then they will be allowed only if the levels are therapeutic., Subjects taking proton pump inhibitors and unwilling to discontinue therapy for two days before and during the study drug dosing periods., Anti-arrhythmic medications known to cause QTc prolongation, Tyrosine kinase inhibitor therapy, Subjects with an abnormal Complete Blood Count (clinically insignificant changes would be acceptable based on the judgement of the investigators), Subjects on antiplatelet agents (Clopidogrel; Dipyridamole + ASA; ASA, Ticagrelor; Prasugrel; Ticlopidine or other) who are unable or unwilling to reduce or hold therapy prior to and during the study drug dosing periods and collection of bone biopsies. Subjects may continue their previous regimen between study drug dosing periods., Known allergy to dasatinib, quercetin, or NR, Subjects taking the following antimicrobial agents: Aminoglycosides, Azole antifungals (fluconazole, miconazole, voriconazole, itraconazole), Macrolides (clarithromycin, erythromycin), antivirals (nelfinavir, indinavir, saquinavir, ritonavir, elbasvir/grazoprevir), Presence of any condition the Investigator believes would place the subject at risk or would preclude the subject from successfully completing all aspects of the trial e.g., heart failure, malignancy etc., QTc >470 msec, T-score <-2.5 at the hip or lumbar spine. These individuals may be included if they prefer to participate or are not candidates for conventional osteoporosis therapies, Inability to take oral medication, Inability to provide fasting blood samples, Primary hyperparathyroidism, Vitamin D deficiency (<50 nM) (re-test after substitution acceptable), Known disorders affecting bone metabolism, e.g., uncontrolled thyrotoxicosis, severe renal impairment (eGFR <20) or liver function (baseline phosphatase higher than twice upper limit, rheumatism, celiac disease/malabsorption, hypogonadism, severe COPD, hypopituitarism, Cushing's disease, uncontrolled diabetes (HbA1c > 58 mmol/mol)., Antiresorptive or bone anabolic drugs for the last 3 years, Concomitant treatments known to influence bone metabolism e.g., glucocorticoids (systemic treatments), anabolic steroids, etc., Subjects taking the following other drugs if they cannot be held for at least 2 days before and during administration of dasatinib+quercetin: digoxin, lithium, all statins, repaglidine, bosentan, gemfibrozil, olmesartan, enalapril, valsartan, methotrexate, corticosteroids, eluxadoline, eltrombopag, nitroglycerin, pioglitazone, glyburide, enzalutamide, ezetimibe, colchicine, imatinib, cyclosporine, tacrolimus, sirolimus, carbamazepine, flecainide, phenytoin, phenobarbital, rifampicin, theophylline, warfarin, heparin, clopidogrel, celecoxib, desipramine, thioridazine, venlafaxine, tizanidine, atomoxetine, voriconazole, citalopram, diazepam, escitalopram, propranolol, clozapine, cyclobenzaprine, mexiletine, olanzapine, ondansetron

Study & Design

Study Type: Interventional clinical trial of medicinal product

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method

Secondary Outcome Measures

Name	Time	Method

Related Trials